Dr.Roberto Collazo-Maldonado

Love Nephrology and baseball.Partner Dallas Nephrology Associates.This is a personal account. Teaching/practicing/learning Nephrology for living.

[Sandra Herrmann MD, FASN @HerrmannMd]

Thank you, @LilianPalma412, for highlighting our study, just out in @NDTsocial! 🔥#KidneyWk @asnpublications

The only study looking at C5 inhibition with 100% of patients having biopsy-proven TMA!

@MayoClinicNeph @MBarbarini

[JAMA @JAMA_current]

💬 Editorial by Kai-Uwe Eckardt, MD, and Mark Koury, MD: #SGLT2 inhibitors were developed for glycemic control but also consistently increase hemoglobin and hematocrit across patients with cardiovascular disease, heart failure, or chronic kidney disease, with or without diabetes. This additional effect may contribute to multimodal anemia management while accompanying the established cardiovascular and kidney benefits of this drug class.

https://t.co/QQ39GpMHsb

#KidneyWk @ASNKidney

[soda_troubles, I have faith in Discord. @set_fortess]

Armanni-Ebstein Lesions Associated With SGLT2 Inhibitor Therapy
https://t.co/Soerfq3Das

[Anil Makam @AnilMakam]

Yes. Competing outcome of death is monumentally higher than ESRD. This is why gfr slope reduction or other kidney enpoints for HTN/diabetes ckd misses the boat. Honestly, if you are a nephrologist, doing primary and secondary prevention for CVD through risk factor modification is way higher value than worrying about Hgb, product, or Vit D

[Rajiv Agarwal MD, MS @AgarwalRajivMD]

Apparent resistant hypertension affected about 40% of people with CKD and type 2 dm in CONFIDENCE. Finerenone plus empagliflozin lowered BP more than either drug alone, on par with spironolactone but without its hyperkalemia burden. Now in JACC: Advances: https://t.co/0Ubo3xpu8m

[Joel M. Topf, MD FACP @kidney_boy]

Most people with CKD don't make it to dialysis. They die of CVD.

[Joel M. Topf, MD FACP @kidney_boy]

For those of you who slept in here is @jordy_bc's speech

[Eric Weinhandl @eric_weinhandl]

The most important figure in the new USRDS Annual Data Report. #KidneyWk

[Ladan Zand @LadanZand]

Don’t forget to checkout our oral presentation tomorrow. @basmeomeo will discuss the concept of CLL or renal significance.

[Eric Weinhandl @eric_weinhandl]

Thanks a lot, Hurricane Helene. No matter, the home dialysis train cannot be stopped. #KidneyWk

[Joel M. Topf, MD FACP @kidney_boy]

Amazing opening slide

[Dr.Roberto Collazo-Maldonado @collazor1]

‘ growing up I had a front seat to courage’ 👏👏👏👏

[UTSW Nephrology @UTSWNephrology]

💙 An inspiring start to #KidneyWk 2026!

Dr. Samir Parikh @samirparikhmd, ASN President, opens his Presidential Address with a powerful message about COURAGE.

A reminder of the courage it takes to lead, innovate, and advance kidney care. 🫘

#UTSWNephroly @UTSWInternalMed

[NEJM @NEJM]

Presented at #KidneyWk:

In patients with IgA nephropathy, atacicept, a human TACI–Fc fusion protein that modulates B-cell activity, slowed and stabilized the decline in the eGFR as compared with placebo. Full phase 3 ORIGIN 3 trial results: https://t.co/vNEvYf4Ao1

@ASNKidney

[NEJM @NEJM]

Presented at #KidneyWk:

In a phase 3, double-blind, randomized trial involving patients with IgA nephropathy, sibeprenlimab stabilized the eGFR slope over 24 months, consistent with a reduced risk of kidney-function decline. Full VISIONARY trial results: https://t.co/T8euA518cz

@ASNKidney

[Mayo Clinic Nephrology @MayoClinicNeph]

“A Phase 2 Open-Label Trial Evaluating the Efficacy and Safety of Daratumumab in Treatment of Patients with Active Lupus Nephritis (LN)”

#ASNKidneyWeek2026 and discuss an exciting Mayo Clinic research project!
@LadanZand @fervenzaf @mvargas07 @AnilaCara @wisit661

[UTSW Nephrology @UTSWNephrology]

💙 An inspiring start to #KidneyWk 2026!

Dr. Samir Parikh @samirparikhmd, ASN President, opens his Presidential Address with a powerful message about COURAGE.

A reminder of the courage it takes to lead, innovate, and advance kidney care. 🫘

#UTSWNephroly @UTSWInternalMed

[Vincent Rajkumar @VincentRK]

More data is good. And I appreciate intent of the article. Nelson Leung whos my friend and colleague (and writers the light chain cast nephropathy management section on UpToDate) is on the paper. My problem is the conclusion. Thats way behind and too confident for what a retrospective study can reveal and if physicians or patients actually take that to heart and implement or if insurance rejects approval can and will cause harm. The tweet that I saw promoted the conclusion. Thats what people see. Not the previous sentence that there was benefit in newly diagnosed.

I don’t remember the last time we plexed a patient with relapsed MM with cast nephropathy. It’s really uncommon to have that presentation in today’s Myeloma practice. I’m mainly concerned about newly diagnosed MM presenting with acute light chain cast nephropathy and there my message is crystal clear: plex first and ask questions later. Start dara VCd asap. In patient. Advocate for patients to have access even if hospital loses money.

[ASN Publications @asnpublications]

Matthias Kretzler, MD, will receive the Homer W. Smith Award at #KidneyWk. Read more about contributions advancing precision medicine and kidney disease research in #ASNKidneyNews: https://t.co/TizVP0NEYe

[ASN Publications @asnpublications]

Join us at #KidneyWk as physician, comedian, and health care advocate William Flanary, MD, receives the ASN President's Medal.
Read more in #ASNKidneyNews: https://t.co/JGTiIAtRSt
@@DGlaucomflecken

[Shruti Gupta @ShrutiGkidney]

@VincentRK Thanks for your comments. However, I would like to highlight that there are very few patients in practice that receive both Dara and plex - mayo is unique that way.
The target trials were separate and were intended to look at each treatment individually, not together.